Similarly, the pionERA breast cancer trial (NCT06065748) compares giredestrant plus a CDK4/6 inhibitor of physicians’ choice with fulvestrant plus a CDK4/6 inhibitor of physicians’ choice in the first-line treatment of ER+ HER2− metastatic breast cancer. This evidence concerns the gene CDK4 and breast cancer.